Novartis external funding application process

Novartis may provide external funding to legitimate organisations in the interest of driving its mission to improve healthcare, advance scientific/medical knowledge or support the communities where Novartis Associates live and work.

The applicant will be responsible for the application, content and implementation of any activity that receives Novartis support, including compliance with laws and regulations.

Applying for funding

Applications must outline a clear and defined purpose and transparent objectives, deliverables, milestones and outcomes as appropriate.  Applications will only be accepted from legitimate organisations. Furthermore funding support can only be provided to legitimate organisations and not to individuals.  Applications on this platform will only be accepted for the categories below.

All applications should relate directly to one or more Novartis Areas of Interest.

Funding may be provided in the form of:


Unsolicited, independently requested monetary contribution for a specified purpose to support medical/scientific research, education, policy initiatives, and patient advocacy activities where Novartis will receive no benefit.  Grants will not be provided to political parties.

How do I submit a request for funding?

Requests should be submitted to the GEMS portal by clicking here. Guidance on using the portal is available here.

How are requests evaluated?

Once received, each request will be reviewed carefully and fairly by the appropriate Novartis experts with every effort made to provide a response once we have all the necessary information. Please note that your request will be assessed in consideration of applicable local laws and regulations.

Rate this content: 
No votes yet

Ask Speakers


Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website Adverse events can also be reported to Novartis preferably at, by emailing [email protected] or by calling (01) 2080 612.